Acute myeloid leukaemia
A Khwaja, M Bjorkholm, RE Gale, RL Levine… - Nature reviews Disease …, 2016 - nature.com
Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
H Döhner, EH Estey, S Amadori… - Blood, The Journal …, 2010 - ashpublications.org
In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
LK Schmalbrock, A Dolnik, S Cocciardi… - Blood, The Journal …, 2021 - ashpublications.org
In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …
Therapeutic advances in acute myeloid leukemia
A Burnett, M Wetzler, B Löwenberg - Journal of clinical oncology, 2011 - ascopubs.org
The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group …
G Marcucci, K Maharry, YZ Wu… - Journal of clinical …, 2010 - ascopubs.org
Purpose To analyze the frequency and associations with prognostic markers and outcome of
mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo …
mutations in IDH genes encoding isocitrate dehydrogenases in adult de novo …
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
AK Burnett, RK Hills, D Milligan, L Kjeldsen… - Journal of clinical …, 2011 - ascopubs.org
Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications
G Marcucci, T Haferlach, H Döhner - Journal of Clinical Oncology, 2011 - ascopubs.org
Molecular analyses of leukemic blasts from patients with acute myeloid leukemia (AML)
have revealed a striking heterogeneity with regard to the presence of acquired gene …
have revealed a striking heterogeneity with regard to the presence of acquired gene …
[HTML][HTML] Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition
BZ Carter, PY Mak, W Tao, M Warmoes… - …, 2022 - ncbi.nlm.nih.gov
Abstract MCL-1 and BCL-2 are both frequently overexpressed in acute myeloid leukemia
(AML) and critical for the survival of AML cells and AML stem cells. MCL-1 is a key factor in …
(AML) and critical for the survival of AML cells and AML stem cells. MCL-1 is a key factor in …
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute …
D Cilloni, A Renneville, F Hermitte, RK Hills… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Risk stratification in acute myeloid leukemia (AML) is currently based on
pretreatment characteristics. It remains to be established whether relapse risk can be better …
pretreatment characteristics. It remains to be established whether relapse risk can be better …
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene …
JH Mendler, K Maharry, MD Radmacher… - Journal of clinical …, 2012 - ascopubs.org
Purpose To determine the association of RUNX1 mutations with therapeutic outcome in
younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN …
younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN …